Table 2.
Information on the autopsy cohort.
| LBD−AD | LBD+AD | |
|---|---|---|
| Number (female) | 14 (0) | 7 (1) |
| MRI‐death interval‐months (std) | 21 (16) | 21 (14) |
| Brain weight 1 | 1346 (116) | 1349 (115) |
| Braak stage 2 | ||
| 0 | 2 | 0 |
| 1 | 10 | 0 |
| 2 | 2 | 5 |
| 3 | 0 | 2 |
| CERAD 2 | ||
| 0 | 9 | 0 |
| 1 | 2 | 1 |
| 2 | 2 | 2 |
| 3 | 1 | 4 |
| Thal phase 2 | ||
| 0 | 9 | 0 |
| 1 | 0 | 0 |
| 2 | 3 | 1 |
| 3 | 2 | 6 |
| AD copathology 2 | ||
| None | 9 | NA |
| Low | 5 | NA |
| Intermediate | NA | 5 |
| High | NA | 2 |
| McKeith stage | ||
| Brainstem | 3 | 0 |
| Limbic | 4 | 1 |
| Neocortical | 7 | 6 |
| Other copathology 2 , 3 | ||
| HS | 0 | 1 |
| LATE | 1 | 2 |
| AGD | 1 | 0 |
LBD−AD, Lewy body disorders without evidence of clinically significant Alzheimer’s copathology; LBD+AD, Lewy body disorders with evidence of clinically significant Alzheimer’s copathology; AD, Alzheimer’s disease. AGD, argyrophilic grain disease; HS, hippocampal sclerosis; LATE, limbic‐predominant age‐related TDP‐43 encephalopathy; LBD, Lewy body disorder; NA, not applicable; SD, standard deviation.
1
Grams (std).
2
Number.
3
One LBD−AD patient had PSP co‐pathology largely confined to the brainstem and subcortical regions confirmed by Thioflavin S to differentiate AD tau neurofibrillary tauopathy from PSP tautopathy for Braak staging.